Sunstone still has faith in gains from investment in failed Galecto
”I still believe that they will find a way to get that drug out into the world,” says the managing partner of major investor Sunstone Life Science Ventures.
It is too early to put the biotech company Galecto Biotech in the grave and completely rule out all hope for the company, even though it recently failed in a crucial phase II trial with the lead candidate GB0139, which has therefore been scrapped.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Low share price may knock Galecto off the stock exchange
For subscribers
